Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Sep 26, 2021; 13(9): 1293-1306
Published online Sep 26, 2021. doi: 10.4252/wjsc.v13.i9.1293
Empty nose syndrome pathogenesis and cell-based biotechnology products as a new option for treatment
Inna M Gordiienko, Olga S Gubar, Roman Sulik, Taras Kunakh, Igor Zlatskiy, Alona Zlatska
Inna M Gordiienko, Roman Sulik, Taras Kunakh, Alona Zlatska, Biotechnology Laboratory, Medical Company “Good Cells”, Kyiv 03115, Ukraine
Inna M Gordiienko, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology NAS of Ukraine, Kyiv 03022, Ukraine
Olga S Gubar, Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv 03143, Ukraine
Igor Zlatskiy, Alona Zlatska, State Institute of Genetic and Regenerative Medicine, National Academy of Medical Sciences of Ukraine, Kyiv 04114, Ukraine
Author contributions: All authors contributed equally to this work.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Igor Zlatskiy, PhD, Senior Researcher, State Institute of Genetic and Regenerative Medicine, National Academy of Medical Sciences of Ukraine, Vyshgorodskaja Street, 67, Kyiv 04114, Ukraine. zlatskiy@ukr.net
Received: February 28, 2021
Peer-review started: February 28, 2021
First decision: April 19, 2021
Revised: April 29, 2021
Accepted: August 13, 2021
Article in press: August 13, 2021
Published online: September 26, 2021
Processing time: 201 Days and 22.2 Hours
Abstract

Empty nose syndrome (ENS) is a rare complication that develops after partial or complete turbinectomy. The main feature of ENS is paradoxical nasal obstruction feeling despite objectively wide nasal airway. ENS pathogenesis is multifactorial and includes changes in laminar physiological airflow, disruption of mucosa functions and deficient neural sensation. This leads to the development of ENS symptomatology such as dyspnea, nasal dryness, nasal burning, nasal obstruction, feeling of suffocation and even comorbid psychiatric disorders that significantly impairs life quality. Specific effective treatment of ENS does not exist up to date. In this review we outline existing biomaterial for surgical reconstitution of nasal anatomy and discuss the perspective of stem cell-based technologies in ENS management. The main focus is directed to justification of rationality application of adult mesenchymal stem cells (MSCs) from different tissues origin and neural crest-derived stem cells (NCSCs) based on their intrinsic biological properties. MSCs transplantation may stimulate mucosa tissue regeneration via trophic factors secretion, direct transdifferentiation into epithelial cells and pronounced immunosuppressive effect. From the other hand, NCSCs based on their high neuroprotective properties may reconstitute nerve structure and functioning leading to normal sensation in ENS patients. We postulate that application of cell-based and tissue-engineered products can help to significantly improve ENS symptomatology only as complex approach aimed at reconstitution of nasal anatomy, recovery the nasal mucosa functionality and neural tissue sensation.

Keywords: Empty nose syndrome; Stem-cell-based technologies; Implants biomaterials; Grafts; Hydrogels; Mesenchymal stem cells

Core Tip: Empty nose syndrome is a complex disease, which pathogenesis is associated not only with changes in the architecture of the nasal passages, but also with changes in the receptor status of the nasal mucosa and disorders of perception of external stimuli at the systemic level. Due to the lack of effective convencial protocols for the treatment of this disease, there is a need to find new approaches to restoring the normal structure of the architecture of the nasal passages and return the functionality of the nasal mucosa. In addition, the proposed methods should be minimally invasive, implemented by injection. The advancement of regenerative medicine and biotechnology contributes to the development of new cell-based products in combination with various materials, which in the future will be able to help develop protocols for treatment patients with empty nose syndrome.